Data Sheet (Cat.No.T32188)

TargetMol

IPI-493

Chemical Properties



CAS No. : 64202-81-9

Formula: C28H39N3O8

Molecular Weight: 545.62

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	IPI-493 (17-amino17demethoxy) is a novel HSP90 inhibitor with antitumor activity.
Targets(IC50)	HSP
In vivo	In Nude mice of GIST-BOE, the oral doses of IPI-493 were 50 mg/kg twice daily, 40 mg/kg once daily, and 100 mg/kg three times weekly. In the GIST-PSW and GIST-48 models, the dose of IPI-493 was reduced to 80 mg/kg with no change in the duration of dosing.IPI-493 treatment resulted in tumor growth stabilization, different degrees of proliferation inhibition, induction of apoptosis and necrosis, and down-regulation of the KIT and its signaling cascade, especially in the GIST-BOE model.IPI-493 treatment significantly reduced vascular density.[5]

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.8328 mL	9.1639 mL	18.3278 mL
5 mM	0.3666 mL	1.8328 mL	3.6656 mL
10 mM	0.1833 mL	0.9164 mL	1.8328 mL
50 mM	0.0367 mL	0.1833 mL	0.3666 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Porter, James R., et al.Ansamycin hydroquinone compositions for the treatment of hyperproliferative disorders. PCT Int. Appl. (2010), 101pp. CODEN: PIXXD2 WO 2010045442 A1 20100422 CAN 152:493438 AN 2010:499720

Porter, James R.et al. Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy. Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates) (2009), 9(15), 1386-1418. CODEN: CTMCCL ISSN:1568-0266. CAN 152:421418 AN 2010:152784

Douglas,et al.The antiproliferative activity of the heat shock protein 90 inhibitor IPI-504 is not dependent on NAD (P)H:quinone oxidoreductase 1 activity in vivo. Molecular Cancer Therapeutics (2009), 8(12), 3369-3378. CODEN: MCTOCF ISSN:1535-716CAN 152:206394 AN 2009:1541742

Floris G, et al. The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations. Clin Cancer Res. 2011 Sep 1;17(17):5604-14.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481